Deferral of Annual General Meeting
Released
Released
Announcement PDF
ASX Announcement
25 March 2020
ASX Market Announcements
ASX Limited
Level 4
Stock Exchange Centre
20 Bridge Street
Sydney NSW 2000
Deferral of Annual General Meeting
Melbourne, Australia, 25 March 2020 – Avecho Biotechnology Limited (ASX: AVE) (“Company”), an
Australian drug delivery company, advises that due to the current restrictions arising from the COVID-19
containment efforts and in line with recent advice received from the Australian Securities & Investments
Commission (“ASIC”), it has decided to defer its Annual General Meeting (“AGM”) which was due to be held
on 14 May 2020.
ASIC has recently provided the advice that it will take a no action stance if an entity postpones its AGM for
two months, being until the end of July 2020.
ASIC is cautioning entities against holding an AGM while current restrictions on large gatherings are in place.
They are continually reviewing their position on this day to day and as the situation evolves.
In light of this advice and as previously noted, the Company has determined to defer its AGM, and this
will consequently defer the closing date for receipt of nominations for the position of Director as
announced on 17 March 2020. The Company will provide further information when it becomes available.
For enquiries, please contact
Melanie Leydin
Company Secretary
+61 3 9692 7222
This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.
About Avecho
Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human Health, Animal
Health and Personal Care products using its proprietary drug delivery system called TPM® (Targeted
Penetration Matrix). TPM® is derived from Vitamin E using unique, proprietary and patented processes and
is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.
Avecho’s major projects include delivering TPM® enhanced patches, gels and injectable products for the
human health market and is also developing TPM® to enhance the feed efficiency and health of livestock.
See more here - avecho.com.au
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
avecho.com.au
Share your feedback
Discover